Clinical trials
MCL clinical trials
Below are recruiting mcl clinical trials, each written for real people, not researchers. We’re tracking 43 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06496308RecruitingPhase 3
Adding orelabrutinib to standard therapy for mantle cell lymphoma
This trial tests adding the targeted therapy orelabrutinib (a BTK inhibitor) to standard chemotherapy (bendamustine) and immunotherapy (rituximab) for people with high-risk mantle cell lymphoma who have not had treatment before. The goal is to see if the combination works better at controlling the cancer.
ShanghaiAges 18–80 - NCT07719556RecruitingPhase 2
Orelabrutinib with obinutuzumab and venetoclax for untreated MCL
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Changzhou, JiangsuAges 18 years+ - NCT07460362RecruitingPhase 2
Glofitamab and lenalidomide for high-risk mantle cell lymphoma
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
Beijing, Beijing MunicipalityAges 18–80 - NCT07257055RecruitingPhase 2
New drug combo for aggressive mantle cell lymphoma
This trial tests a two-step treatment for people with a fast-growing form of mantle cell lymphoma (MCL). First, you take a daily pill (BTKi) plus an infusion (rituximab), then a newer targeted therapy (glofitamab) to try to make the response last. The goal is to shrink the cancer and keep it away.
Houston, TexasAges 18 years+ - NCT07199296RecruitingPhase 2
Study of orelabrutinib and rituximab with optional stem cell transplant for mantle cell lymphoma
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
ShanghaiAges 14 years+ - NCT06463691RecruitingPhase 2
Sonrotoclax, Zanubrutinib, and CD20 Antibody for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs—sonrotoclax, zanubrutinib, and a CD20 antibody—as a first treatment for mantle cell lymphoma. It aims to see if this new combination is safe and effective for patients who have not yet received any treatment.
TianjinAges 18 years+ - NCT06850168Recruiting
Can special glasses slow down nearsightedness in children?
This trial tests a new type of spectacle lens designed to slow the progression of nearsightedness (myopia) in children. If your child is between 6 and 10 years old, has mild to moderate nearsightedness, and is willing to wear glasses full-time for two years, this study may be a good fit.
SingaporeAges 6–11 - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT03869619Recruiting
Real-life data study for adults with recent lymphoma
This study collects “real-world” health information about adults whose lymphoma was diagnosed within the last 6 months. It aims to better understand lymphoma types and how patients do over time, using data from everyday care rather than testing a new drug.
ArrasAges 18 years+ - NCT05992597RecruitingPhase 2
ZR2 follow-up immunotherapy for newly diagnosed mantle cell lymphoma
This trial tests a new combination of drugs (ZR2 followed by chemoinmunotherapy) for people newly diagnosed with mantle cell lymphoma. It aims to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT07788118RecruitingPhase 1/Phase 2
A new car-t therapy for relapsed large b-cell lymphoma
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
Hangzhou, ZhejiangAges 18–75 - NCT05255354Recruiting
Testing blood cancer DNA monitoring during CAR-T treatment
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Palo Alto, CaliforniaAges 18 years+ - NCT07609862RecruitingPhase 1/Phase 2
Rocbrutinib and Lacutoclax for B-Cell Blood Cancers
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
TianjinAges 18 years+ - NCT06363994RecruitingPhase 3
Study of orelabrutinib plus BR for untreated mantle cell lymphoma
This trial tests a new combination of drugs (orelabrutinib plus BR) compared to BR alone for people with newly diagnosed mantle cell lymphoma who have not had treatment before. It may be an option if you are older or not able to have a stem cell transplant.
BeijingAges 60 years+ - NCT07453095RecruitingPhase 2
Glofitamab for mantle cell lymphoma after CAR T-cell therapy
This trial tests a new drug called glofitamab for people with mantle cell lymphoma (MCL) whose cancer did not respond or came back after CAR T-cell therapy. Glofitamab is a type of immunotherapy that helps your immune system fight the cancer.
AlessandriaAges 18 years+ - NCT06464861RecruitingPhase 1
Sequential CD19 CAR-NK and CAR-T for B-cell lymphoma
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06788652Recruiting
Study of Liso-cel for mantle cell lymphoma after market approval
This study looks at patients with mantle cell lymphoma who have already received a treatment called lisocabtagene maraleucel (Liso-cel) as part of standard care. It helps researchers understand how well the therapy works in real-world use.
Milwaukee, WisconsinAges 18 years+ - NCT07285590RecruitingPhase 2
Testing pirtobrutinib and rituximab for mantle cell lymphoma
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
Lisbon, Lisbon DistrictAges 18 years+ - NCT07272499RecruitingPhase 2
New drug combo for untreated high-risk mantle cell lymphoma
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT07259070RecruitingPhase 1/Phase 2
CAR T-cells targeting BAFF-R for resistant B-cell lymphoma
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07257510Recruiting
Pomalidomide plus two other drugs for untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people with Mantle Cell Lymphoma who have not yet received treatment. It aims to see if this combination works better than standard therapy, especially for those with high-risk features.
Beijing, Beijing MunicipalityAges 18–80 - NCT07174219Recruiting
Return to sports after MCL knee surgery
This study tracks people who had surgery to reattach the medial collateral ligament (MCL) in the knee, alone or with other repairs. It measures how well and how safely they return to sports. If you had this surgery, you may help improve future care.
Bologna, BolognaAges 12–65 - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT07082686RecruitingPhase 2
A study of ICP-248 for mantle cell lymphoma that has come back or not responded
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
Hefei, AnhuiAges 18 years+
Hear when a new MCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mcl?
- Yes. Clin2 currently lists 43 recruiting mcl studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mcl trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mcl trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.